Free Trial

RAPT Therapeutics (RAPT) News Today

RAPT Therapeutics logo
$1.23 +0.37 (+43.34%)
Closing price 05/23/2025 04:00 PM Eastern
Extended Trading
$1.20 -0.03 (-2.44%)
As of 05/23/2025 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

RAPT Latest News

RAPT Therapeutics, Inc. stock logo
RAPT Therapeutics (NASDAQ:RAPT) Upgraded to "Hold" at Wall Street Zen
Wall Street Zen raised shares of RAPT Therapeutics from a "sell" rating to a "hold" rating in a research report on Thursday.
RAPT Therapeutics, Inc. stock logo
UBS Group Issues Pessimistic Forecast for RAPT Therapeutics (NASDAQ:RAPT) Stock Price
UBS Group decreased their price objective on RAPT Therapeutics from $2.00 to $1.00 and set a "neutral" rating for the company in a report on Thursday.
RAPT Therapeutics, Inc. stock logo
RAPT Therapeutics (NASDAQ:RAPT) Earns Buy Rating from HC Wainwright
HC Wainwright reissued a "buy" rating and set a $6.00 target price on shares of RAPT Therapeutics in a research note on Thursday.
RAPT Therapeutics, Inc. stock logo
11,764,000 Shares in RAPT Therapeutics, Inc. (NASDAQ:RAPT) Acquired by RTW Investments LP
RTW Investments LP purchased a new position in shares of RAPT Therapeutics, Inc. (NASDAQ:RAPT - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 11,764,000 shares of the company's stock, valued at
RAPT Therapeutics, Inc. stock logo
13,135,260 Shares in RAPT Therapeutics, Inc. (NASDAQ:RAPT) Purchased by Orbimed Advisors LLC
Orbimed Advisors LLC purchased a new stake in RAPT Therapeutics, Inc. (NASDAQ:RAPT - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 13,135,260 shares of the company's s
RAPT Therapeutics, Inc. stock logo
RAPT Therapeutics, Inc. (NASDAQ:RAPT) Given Average Rating of "Hold" by Analysts
RAPT Therapeutics, Inc. (NASDAQ:RAPT - Get Free Report) has been given a consensus rating of "Hold" by the nine brokerages that are currently covering the stock, Marketbeat reports. One analyst has rated the stock with a sell rating, six have assigned a hold rating and two have given a buy rating
RAPT Therapeutics, Inc. stock logo
Deep Track Capital LP Invests $9.50 Million in RAPT Therapeutics, Inc. (NASDAQ:RAPT)
Deep Track Capital LP bought a new stake in RAPT Therapeutics, Inc. (NASDAQ:RAPT - Free Report) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 6,011,380 shares of the company's stock, value
RAPT Therapeutics, Inc. stock logo
Column Group LLC Lowers Stock Holdings in RAPT Therapeutics, Inc. (NASDAQ:RAPT)
Column Group LLC lessened its position in shares of RAPT Therapeutics, Inc. (NASDAQ:RAPT - Free Report) by 50.4% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,328,613 shares of the company's stock after
RAPT Therapeutics, Inc. stock logo
BVF Inc. IL Acquires New Position in RAPT Therapeutics, Inc. (NASDAQ:RAPT)
BVF Inc. IL bought a new position in RAPT Therapeutics, Inc. (NASDAQ:RAPT - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 9,237,556 shares of the company's stock, valued at appro
RAPT Therapeutics, Inc. stock logo
RAPT Therapeutics (RAPT) to Release Earnings on Thursday
RAPT Therapeutics (NASDAQ:RAPT) will be releasing its Q1 2025 earnings before the market opens on Thursday, May 8. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-8-rapt-therapeutics-inc-stock/)
RAPT Therapeutics, Inc. stock logo
TCG Crossover Management LLC Buys Shares of 13,135,260 RAPT Therapeutics, Inc. (NASDAQ:RAPT)
TCG Crossover Management LLC purchased a new position in shares of RAPT Therapeutics, Inc. (NASDAQ:RAPT - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 13,135,260 share
RAPT Therapeutics, Inc. stock logo
1,243,513 Shares in RAPT Therapeutics, Inc. (NASDAQ:RAPT) Purchased by Nantahala Capital Management LLC
Nantahala Capital Management LLC bought a new position in RAPT Therapeutics, Inc. (NASDAQ:RAPT - Free Report) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 1,243,513 shares of the company's stock, valued at approxim
RAPT Therapeutics, Inc. stock logo
Foresite Capital Management VI LLC Invests $19.75 Million in RAPT Therapeutics, Inc. (NASDAQ:RAPT)
Foresite Capital Management VI LLC acquired a new position in shares of RAPT Therapeutics, Inc. (NASDAQ:RAPT - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 12,500,000 shares of the company's
RAPT Therapeutics, Inc. stock logo
RAPT Therapeutics, Inc. (NASDAQ:RAPT) Short Interest Update
RAPT Therapeutics, Inc. (NASDAQ:RAPT - Get Free Report) was the target of a large increase in short interest in the month of March. As of March 31st, there was short interest totalling 4,940,000 shares, an increase of 85.0% from the March 15th total of 2,670,000 shares. Currently, 15.1% of the shares of the company are sold short. Based on an average trading volume of 852,200 shares, the short-interest ratio is presently 5.8 days.
Rapt Therapeutics appoints Jessica Savage as VP, clinical development
RAPT Therapeutics, Inc. stock logo
Affinity Asset Advisors LLC Makes New $1.58 Million Investment in RAPT Therapeutics, Inc. (NASDAQ:RAPT)
Affinity Asset Advisors LLC acquired a new stake in RAPT Therapeutics, Inc. (NASDAQ:RAPT - Free Report) during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm acquired 1,000,000 shares of the company's stock, valued at approximately $1
RAPT Therapeutics, Inc. stock logo
RAPT Therapeutics, Inc. (NASDAQ:RAPT) Receives Average Recommendation of "Hold" from Brokerages
Shares of RAPT Therapeutics, Inc. (NASDAQ:RAPT - Get Free Report) have earned an average recommendation of "Hold" from the nine ratings firms that are presently covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, six have given a hold rating
RAPT Therapeutics, Inc. stock logo
ADAR1 Capital Management LLC Grows Position in RAPT Therapeutics, Inc. (NASDAQ:RAPT)
ADAR1 Capital Management LLC raised its stake in shares of RAPT Therapeutics, Inc. (NASDAQ:RAPT - Free Report) by 15,557.5% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,174,313 shares of the company's st
Adaptimmune Therapeutics (ADAP) Receives a Hold from Wells Fargo
RAPT Therapeutics, Inc. stock logo
RAPT Therapeutics, Inc. (NASDAQ:RAPT) Receives Consensus Recommendation of "Hold" from Analysts
RAPT Therapeutics, Inc. (NASDAQ:RAPT - Get Free Report) has received a consensus rating of "Hold" from the nine analysts that are currently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, six have given a hold recommendation and
Rapt Therapeutics reports Q4 EPS ($1.14), consensus (36c)
RAPT Therapeutics, Inc. stock logo
RAPT Therapeutics, Inc. (NASDAQ:RAPT) Receives Average Rating of "Hold" from Analysts
Shares of RAPT Therapeutics, Inc. (NASDAQ:RAPT - Get Free Report) have been assigned an average recommendation of "Hold" from the thirteen research firms that are presently covering the stock, MarketBeat reports. One analyst has rated the stock with a sell recommendation, nine have issued a hold
RAPT Therapeutics, Inc. stock logo
Short Interest in RAPT Therapeutics, Inc. (NASDAQ:RAPT) Grows By 25.5%
RAPT Therapeutics, Inc. (NASDAQ:RAPT - Get Free Report) was the target of a significant increase in short interest during the month of December. As of December 15th, there was short interest totalling 1,720,000 shares, an increase of 25.5% from the November 30th total of 1,370,000 shares. Based on an average trading volume of 2,800,000 shares, the days-to-cover ratio is presently 0.6 days.
Positive Report for RAPT Therapeutics (RAPT) from H.C. Wainwright
Rapt Therapeutics upgraded to Buy from Neutral at H.C. Wainwright
RAPT Therapeutics, Inc. stock logo
RAPT Therapeutics (NASDAQ:RAPT) Upgraded to "Buy" at HC Wainwright
HC Wainwright upgraded RAPT Therapeutics from a "neutral" rating to a "buy" rating and set a $10.00 price target on the stock in a research report on Thursday.
Rapt Therapeutics price target raised to $6 from $4 at Wells Fargo
Get RAPT Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for RAPT and its competitors with MarketBeat's FREE daily newsletter.

RAPT Media Mentions By Week

RAPT Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

RAPT
News Sentiment

0.47

0.77

Average
Medical
News Sentiment

RAPT News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

RAPT Articles
This Week

6

2

RAPT Articles
Average Week

Get RAPT Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for RAPT and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools


This page (NASDAQ:RAPT) was last updated on 5/25/2025 by MarketBeat.com Staff
From Our Partners